Biotech startup ecosystem
Europe's biotech ecosystem benefits from world-class research universities, strong IP frameworks, and growing specialist VC funds. The UK, Switzerland, and the Nordics are particularly strong in drug discovery, diagnostics, and synthetic biology. We track 103 organisations in this sector across 6+ countries.
Showing 61–80 of 103 Biotech
Countries in this sector
Sectors alongside this one
Biotech results
-
Longenesis
Longenesis is a Riga-based digital health company founded in 2017 that builds platforms connecting pharmaceutical companies, healthcare providers, and patients to accelerate biomedical research. Its three core products — Curator, Themis, and Engage — enable privacy-preserving patient cohort discovery, consent management, and real-world evidence generation. The company has positively impacted over 850,000 patients across the EU and MENA, holds partnerships with Medtronic and Novartis, and has raised over €1 million in seed funding. It won second place at the EIT Health Catapult programme and earned an AWS Industry Award in 2023.
-
Manus Rogan
Managing Partner and co-founder of Fountain Healthcare Partners, Ireland's largest dedicated life-sciences fund, which he established in 2008 after a career at Elan and GlaxoSmithKline. He has led biotech investments behind exits including Inflazome (Roche) and Calypso Biotech (Novartis).
-
Marianne Hyltoft
Founder and Managing Partner of PSV Hafnium, the Nordic deep-tech fund she co-launched in 2024. She focuses on industrial biotech, energy, robotics and future-of-compute spinouts, helping technical founders commercialise research with patient venture capital.
-
Melanos Care
Biotech skincare startup developing bio-identical melanin from stem-cell-based processes to improve UV protection and skin health. The company focuses on long-duration photoprotection and alternatives to conventional sunscreen formulations.
-
Mewery
Mewery is a food-tech and biotech startup cultivating pork meat using microalgae-based processes. The hybrid approach reduces the cost and complexity of lab-grown meat by combining cell cultivation with plant inputs. This positions the company to deliver cultured meat products faster and at lower price points than traditional cellular agriculture methods. By 2026, Mewery is a notable Central European pioneer in sustainable protein.
-
MicroHarvest
MicroHarvest produces microbial protein using agricultural side streams and a rapid fermentation process designed to deliver sustainable protein ingredients in around 24 hours. The company reported over USD 10.2M in venture funding from investors such as Astanor, Happiness Capital, Simon Capital, and FoodLabs, and received a EUR 5.5M German government grant in February 2026 for an industrial-scale Leuna plant expected to produce about 15,000 tonnes of protein annually.
-
Mosa Meat
Mosa Meat is a Maastricht-based food-technology company founded in 2016 by the team behind the world's first cultured hamburger, presented in 2013. It develops cultivated (lab-grown) beef produced from animal cells rather than slaughtered livestock, aiming to make real meat with a far smaller environmental footprint as it works toward regulatory approval and scale-up.
-
mRNA-Based Therapeutics Summit Europe 2026
Dedicated summit in Berlin for mRNA-based therapeutics, bringing together pharma executives, biotech researchers, and clinical development leaders. Covers R&D breakthroughs, manufacturing scale-up, and regulatory pathways for mRNA technologies in Europe. Relevant for biotech startups working on next-generation mRNA platforms and delivery systems.
-
MultiplexDX
MultiplexDX focuses on precision cancer diagnostics, developing visualized diagnostic tests aimed at reducing misdiagnosis in oncology. Its work is particularly focused on breast cancer and improving clinical decision confidence. By 2026, the company is a high-impact biotech research player in the Slovak ecosystem with expanding clinical collaborations.
-
Neoplants
Neoplants is one of Europe's most consumer-friendly deep-tech startups, known for engineering "plants with a purpose." Its flagship product, Neo P1, is a golden pothos that has been genetically modified to actively metabolize volatile organic compounds (VOCs) such as formaldehyde and benzene—pollutants common in homes due to paint, furniture, and cleaning products. Rather than simply filtering air passively, the plant converts toxins into harmless sugars and amino acids, turning living organisms into functional indoor air purifiers. The company began commercial sales in the United States, where GMO consumer regulations are more permissive, but 2026 marks a strategic pivot back to Europe. Neoplants is positioning itself to launch in the UK and select EU markets as the New Genomic Techniques (NGT) framework evolves. This regulatory shift is crucial: it could unlock a path for consumer biotech products to be sold in Europe at scale. Neoplants is actively engaging with regulators and policymakers to ensure its products meet safety and transparency standards, framing its technology as a climate and public-health benefit rather than a controversial GMO niche. Neoplants is also a serious biotech company under the consumer-friendly brand. It operates a 12,000-square-foot R&D facility in Saint-Ouen, Paris, with capabilities closer to a pharma lab than a greenhouse. The 2026 R&D pipeline includes plants engineered to capture CO2 at orders-of-magnitude higher rates than typical trees, targeting corporate offices and commercial spaces where sustainability investments must be visible and measurable. That positions Neoplants for a dual-market strategy: consumer air purification today, B2B climate infrastructure tomorrow. The company's ecosystem roots are strong. The founders, Lionel Mora and Patrick Torbey, met at Entrepreneur First in Paris, and Neoplants was an early resident at Station F. It also benefited from the Wilco healthcare and biotech accelerator. Its investors reflect the blend of deep-tech and consumer focus: True Ventures led the seed, Heartcore Capital and Collaborative Fund support the consumer angle, and angels such as Niklas Zennstrom and Xavier Niel provide strategic visibility. In 2026, Neoplants represents a "solarpunk" vision of European tech—advanced biology that is both functional and approachable, turning climate and health solutions into products people can live with.
-
Neurent Medical
Neurent Medical is a Galway-based medtech company developing the NEUROMARK device, which uses proprietary Impedance Controlled Radiofrequency technology to target overactive posterior nasal nerves and treat chronic rhinitis — a condition affecting over 500 million people globally. Founded in 2015, the company closed an oversubscribed €62.5 million Series C in February 2026, led by MVM Partners with participation from Sofinnova Partners, EQT Life Sciences, Atlantic Bridge, and Enterprise Ireland, bringing total funding to over €100 million.
-
New Dawn Bio
Grows wood from tree stem cells in bioreactors without logging, producing material far faster than conventional forestry. Founded in 2023 on Wageningen Campus, it raised an oversubscribed €2.1M pre-seed to advance cultured-wood technology.
-
Nightingale Health
Nightingale Health is the global leader in NMR-based metabolomics, quantifying 250 blood biomarkers from a single sample to enable large-scale disease risk detection and prevention. Founded in Helsinki, it completed the analysis of all 500,000 UK Biobank samples, creating the world's largest blood biomarker database. Listed on Nasdaq Helsinki Main Market since March 2025, the company is deploying its technology into Finnish public healthcare in 2026 through wellbeing services counties. It also partnered with Alamar Biosciences to expand into brain health proteomics.
-
Nordic Innovation Fair 2026 (September 2026)
A two-day Nordic deep-tech and research-commercialisation matchmaking fair at Industriens Hus in Copenhagen under the 2026 theme of defence, resilience and safety. Tracks cover quantum, AI and digital, greentech and food, biotech and pharma, and medtech and diagnostics, connecting startups, researchers and industry across the Nordics.
-
Novo Holdings
Novo Holdings is the investment arm of the Novo Nordisk Foundation and the largest life science investor in Denmark. It backs biotech, medtech, and health innovation across seed, venture, and growth stages while also managing the foundation's long term ownership in Novo Nordisk and Novozymes. The firm provides patient capital, deep scientific expertise, and global networks for founders building therapies, diagnostics, and industrial biotech solutions. Novo Holdings is a cornerstone of the Danish life science ecosystem.
-
Ochre Bio
Ochre Bio is an Oxford-based biotech startup combining computational genomics, machine learning, and RNA therapeutics to develop treatments for chronic liver diseases. Founded in 2019, the company uses human donor livers and large-scale transcriptomic data to identify novel drug targets, then designs RNA-based therapies to address conditions such as NASH and liver fibrosis. Ochre Bio has raised significant venture funding and works with transplant centers to validate its candidates in perfused human organs.
-
Owkin
Owkin is a Paris-based AI biotech founded in 2016 that applies machine learning and federated learning across hospital and pharmaceutical datasets to discover drug targets, develop diagnostics and de-risk clinical trials. It partners with pharmaceutical companies including Sanofi and Bristol Myers Squibb, reached unicorn status, and has more recently launched agentic AI tools for biopharma research.
-
Panakès Partners
Founded in 2015, Panakes Partners is a Milan-based healthcare VC investing EUR 1-8M at Series A and B in medical devices, diagnostics, digital health, and biotech across Europe. The firm manages over EUR 100M and focuses on companies with clear clinical evidence and regulatory pathways. Portfolio includes MMI (surgical robotics, IPO on Euronext), Novavido, and Kither Biotech. The team of medtech executives and clinicians provides hands-on support in clinical trials, CE marking, and commercialization.
-
Pharmacelera
Pharmacelera is a Barcelona-based computational drug discovery company headquartered at the Parc Cientific de Barcelona, combining computer-aided drug design, AI and machine learning, and high-performance computing to explore larger and more diverse chemical space. Its software suite, including PharmScreen, exaScreen, and PharmQSAR, helps pharma and biotech companies with target identification, hit identification, hit-to-lead, and lead optimization by finding novel hits and improving ligand binding properties. Clients referenced on its site include Sanifit Laboratoris and Wren Therapeutics.
-
Pikralida
Biotech drug-discovery company developing PKL-021, a small-molecule MMP inhibitor program for acute neuroprotection after stroke and traumatic brain injury, with additional applications in field-ready snakebite treatment.
